Low-dose Sargramostim Shows Promise in Small Early Trial

Low-dose Sargramostim Shows Promise in Small Early Trial

294875

Low-dose Sargramostim Shows Promise in Small Early Trial

Treatment with a low dose of the immune-modulating medication sargramostim was well-tolerated and eased motor symptoms in a small clinical trial of people with Parkinson’s disease. The results “provide the basis for larger scale assessments to determine clinical efficacy of a reduced sargramostim regimen within the [Parkinson’s] population,” according to researchers. Based on the results, Partner Therapeutics, which markets sargramostim under the brand name Leukine, is planning to seek regulatory approval for further clinical testing…

You must be logged in to read/download the full post.